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Transforming growth factor-beta (TGF-𝛽) is a pleiotropic factor with several different roles in health and disease. In tumorigenesis,
it may act as a protumorigenic factor and have a profound impact on the regulation of the immune system response. Matrix
metalloproteinases (MMPs) are a family that comprises more than 25 members, which have recently been proposed as important
regulators acting in tumor stroma by regulating the response of noncellular and cellular microenvironment. Tumor stroma consists
of several types of resident cells and infiltrating cells derived from bone marrow, which together play crucial roles in the promotion
of tumor growth andmetastasis. In cancer cells, TGF-𝛽 regulatesMMPs expression, whileMMPs, produced by either cancer cells or
residents’ stroma cells, activate latent TGF-𝛽 in the extracellularmatrix, together facilitating the enhancement of tumor progression.
In this review we will focus on the compartment of myeloid stroma cells, such as tumor-associated macrophages, neutrophils, and
dendritic and mast cells, which are potently regulated by TGF-𝛽 and produce large amounts of MMPs. Their interplay and mutual
implications in the generation of pro-tumorigenic cancer microenvironment will be analyzed.
1. Introduction
Transforming growth factor-beta (TGF-𝛽) is a pleiotropic
factor with several different roles in health and disease
[1]. In cancer, TGF-𝛽 plays a paradoxical role, since it
represses epithelial tumor development in the early steps
of tumorigenesis, while in advanced stages it can stimulate
tumor progression [2, 3]. In epithelial cells, TGF-𝛽 has
antiproliferative and apoptotic roles which enable it to reverse
local mitogenic stimulation in the pretumoral stage in the
epithelium [4]. During the advance of tumorigenesis, carci-
noma cells acquire resistance to the proliferative inhibition
and apoptosis induced by TGF-𝛽. Several mechanisms have
been described to explain the changes in the response of
tumor cells to TGF-𝛽1, includingmutations in themachinery
of TGF-𝛽 signaling, as described below. Interestingly, the
pro-tumoral role of TGF-𝛽 can be achieved either by acting
directly on carcinoma cells or by modulating the crosstalk
between cancer cells and noncancer cells in the tumor stroma
[5]. TGF-𝛽 is produced by carcinoma cells as well as by
the varied tumor stroma-associated cell populations, such
as mesenchymal cells and immune cells (macrophages, neu-
trophils, mast cells, myeloid precursors, and T cells, among
others). Therefore, TGF-𝛽 is accumulated in tumor stroma
because of the oncogenic activation of tumor cells and/or
as a consequence of the infiltration of TGF-𝛽-secreting
inflammatory cells, finally resulting in the enhancement of
tumor malignance [6].
During the advance of tumor, carcinoma cells acquire
the capacity to migrate and invade surrounding tissues and
colonize different organs during metastasis. Matrix metallo-
proteases (MMPs) are a group of mainly extracellular matrix
(ECM) proteolytic enzymes which enable cells tomigrate and
invade [7, 8]. Many of MMPs are tightly transcriptionally
regulated in normal development but are deregulated in
cancer [4]; therefore, their activity and expression are related
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to the worsening in the development of cancer. The expres-
sion of MMPs within tumor stroma is diverse; members
of MMPs can be produced by cancer cells, but the major
source of these enzymes is the stromal cells of the tumor,
including infiltrating immune cells. Different sets of MMPs
are produced by different types of stroma-associated cells and
collectively collaborate to alter the milieu inside and around
the tumor [9, 10]. TGF-𝛽 modulates MMPs expression in
both cancer cells and tumor stroma-associated cells, while
in the tumor microenvironment MMPs activate the latent
secretedTGF-𝛽, producing a harmful cyclewhich contributes
to the worsening of tumor malignance. Here we review the
specific roles and the functional interplay of TGF-𝛽 and
MMPs in tumor stroma-associatedmyeloid linage of immune
cells. The heterotypic reciprocal interaction among TGF-𝛽,
MMPs, and immune cells can function as the promoter of
the events which enhance tumor progression and metastasis
suggesting combined therapies for cancer treatment.
2. Transforming Growth Factor Beta
Mammals express three genetically distinct isoforms of TGF-
𝛽 (TGF-𝛽1, TGF-2, and TGF-3) with high homology and
their human genes are located on chromosomes 19q13, 1q41,
and 14q24, respectively (revised in [1]). TGF-𝛽 initiates
signaling by binding to cell-surface serine/threonine kinase
receptors types I and II (TBRI and TBRII, resp.), which
form a heteromeric complex in the presence of the dimerized
ligand (Figure 1). Binding of TGF-𝛽 to TBRII leads to the
phosphorylation of TBRI, thus activating its kinase domain
[11]. When the receptor complex is activated, it phosphory-
lates and stimulates the cytoplasmatic mediators, Smad2 and
Smad3 [12]. The phosphorylation of Smad2,3 releases them
from the inner face, where they are specifically retained by
Smad anchor for receptor activation (SARA). Further on,
Smad2,3 form a heterotrimeric complex with the common
Smad4, which is then translocated into the nucleus where,
in collaboration with other transcription factors, it binds and
regulates promoters of different target genes [1, 12]. TGF-𝛽1
signaling can be regulated by the expression of other com-
ponents of Smads, the inhibitory Smad proteins (I-Smads:
Smad6 and Smad7). TGF-𝛽 regulates the expression of I-
Smads, which establish a negative feedback loop to control
TGF-𝛽 signaling. Essentially, Smad7 antagonizes TGF-𝛽 by
interacting with TBRI and leading to its degradation [13].
In addition to Smad signaling, TGF-𝛽1 may activate other
intracellular signaling pathways, called non-Smad pathways,
such as mitogen-activated protein kinases (MAPK): ERK1,2,
JNK and p38; PI3K (phosphoinositide 3-kinase)/AKT1,2 and
mTOR, known as cell survival mediators; NF-𝜅B (nuclear
factor 𝜅B), Cyclooxygenase-2, and prostaglandins; and the
small GTPase proteins Ras, Rho family (Rho, Rac1 and
Cdc42), among others [14, 15].
3. The Role of TGF-𝛽 in Cancer
As already mentioned, TGF-𝛽 can act either as a tumor
suppressor or as a tumor promoter. Suppression of tumor
cell growth by TGF-𝛽 depends on its ability to upregulate
the cyclin kinase inhibitors which inhibit cell proliferation.
However, as the premalignant lesions progress, they become
refractory to growth inhibition and begin to produce large
amounts of TGF-𝛽. Many malignant tumors have mutated or
downregulated TBRII or other abnormalities in the TGF-𝛽
signaling pathways [2, 3].The importance of TGF-𝛽 signaling
in human cancers is evident from the frequent alterations of
TGF-𝛽 signaling components in hereditary human cancers
and sporadic cancers [16]: for example, the autosomal domi-
nant familial juvenile polyposis syndrome (JPS) is the most
common of the hamartomatous syndromes which occurs
with an incidence of about one per 100.000 births [16–18]
and germline mutations in different members of the TGF-
𝛽 superfamily have been described in JPS patients. Around
15–20% of patients have Smad4 mutations, predominantly in
MH2 domain [19, 20]. In the autosomal dominant disorder
hereditary nonpolyposis colorectal cancer (HNPCC), the
most common hereditary predisposition for the development
of colorectal cancer, TBRII gene contains a 10-base pair
polyadenine repeat microsatellite sequence, and up to 80%
of colon cancer patients with HNPCC present this mutated
form of TBRII [21]. In sporadic cancer, the specific response
to TGF-𝛽 during tumor progression will depend on the stage
of carcinogenesis and the responsiveness of tumor cells, and
can be attributed to both independent and interrelated factors
including changes in: (1) TGF-𝛽 expression; (2) receptor
expression; (3) availability of downstream signaling compo-
nents; (4) evasion of the immune response; (5) stimulation
of inflammation; (6) presence of local and systemic factors
(autocrine, endocrine, paracrine, juxtacrine, or matricrine
interactions); and (7) the recruitment of cell types that lead
to advanced tumor growth or promote angiogenesis [2].
Several tumors express high levels of TGF-𝛽s, which
correlate with tumor progression and clinical prognosis,
making the concerning TGF-𝛽 family members diagnostic,
prognostic, or predictive markers. Hence, increased serum
levels of TGF-𝛽1 have been considered as a prognosticmarker
of advanced disease and poor prognosis in multiple cancer
types such as gastric carcinoma, colorectal cancer, blad-
der carcinoma, prostate cancer, breast cancer, lung cancer,
esophageal adenocarcinoma, andmelanoma. However, TGF-
𝛽 levels are not yet used as tumor markers in clinical routine
[18].
The expression of TGF-𝛽 receptors within tumor cells can
also be used as prognostic markers. For example, reduced
ALK-5/TBRI expression has been described in colon cancer
patients, and two polymorphisms in TBRI (TBRI∗6A and
Int7G24A) have been identified in patients with breast cancer
[16]. Meanwhile, low expression levels of TBRII have been
observed in chronic myeloid leukemia and colon cancer
patients, and mutations in TBRII are frequently found in
colon cancer, gastric cancer, ovarian cancer, and nonsmall
cell lung carcinoma [22]. In a majority of human pancreatic
cancers mutations in TBRI and TBRII that alter protein
and/or mRNA expression levels have been identified [16, 23].
In addition, low levels of TBRI/ALK5 and TBRII expression
in breast cancer have also been associated with epige-
netic silencing [24]. Conversely, some studies suggest that


















































Figure 1: TGF-𝛽 signaling and MMPs interplay. Active TGF-𝛽 binds to its cell-surface type II receptor (TBRII), inducing the activation of
TGF-𝛽 type I receptor (ALK5 or TBRI) and forming a heterotetrameric complex. Then two sets of signaling pathways can be stimulated:
the Smad pathway, where ALK5 phosphorylates Smad2,3 and promotes the release of Smads from the complex with SARA from the inner
face of the plasma membrane (phosphorylated Smad2,3 interact with co-Smad4, forming a heteromeric complex to be translocated into the
cell nucleus) and non-Smad pathways, where active TGF-𝛽-receptor complex interacts with ubiquitin ligase tumor necrosis factor receptor-
associated factor 6 (TRAF6) which in turn recruits TGF-𝛽 activated kinase 1 (TAK1) to activate p38, JNK, or NF𝜅B pathway. On the other
hand, TGF-𝛽 binding provokes the phosphorylation of ALK5 at tyrosine residues which enable the formation of Shc-Grb2/SoS complex to
activate Ras-Raf1-MEK1,2-ERK1,2 signaling. Finally, receptor activated complexes can activate PI3K, provoking the activation of AKT and
the small Rho GTPases. The activation of both Smad and non-Smad signaling pathways in turn initiate transcriptional or nontranscriptional
activity to regulate MMPs expression, thus incrementing the protein levels in tumor microenvironment. When membrane bound MMPs or
soluble MMPs are expressed, they may promote the activation of latent TGF-𝛽 by proteolytic cleavage within the N-terminal region of the
latency-associated peptide (LAP) or the large latent complex (LLC).
ALK5/TBRI and TBRII expression is increased in advanced
human malignant glioma tissues compared to nontumorous
gliosis. In addition, microsatellite instability which carried
TBRII genetic mutations in a particular repeat region of
the TBRII gene has been reported [25, 26]. Finally, TGF-
𝛽 signaling promotes epithelial to mesenchymal transition,
a characteristic of invasive and metastatic cells, leading to
increased metastases in human cancer, as well as in animal
cancer models [3].
4. Matrix Metalloproteinases
The notion that the remodeling of the ECM in tumor plays
a strategic role in the increment of cancer cell malignance is
becoming increasingly accepted. Therefore, ECM degrading
proteases, such as MMPs, are gaining more attention as
mediators of the alterations in tumor stroma, which can
support cancer progression. In addition to the remodeling
of ECM, MMPs exert different roles which are involved in
the promotion or inhibition of tumor progression. MMPs
can contribute to tumor cell proliferation by altering the
bioavailability of growth factors, such as insulin growth
factors (IGFs) and the epidermal growth factor receptor
(EGFR) ligands. Both apoptotic and antiapoptotic actions
of MMPs are also known; for example, the antiapoptotic
signals are transduced to cancer cells by MMP-7’s ability
to cleave Fas ligand, a transmembrane stimulator of the
death receptor Fas, from the cell surface. On the other hand,
MMPs can also promote apoptosis, probably by modulating
the ECM composition, for example, by cleaving laminin,
which influences integrin signaling. SomeMMPs, likeMMP-
2,MMP-9, andMMP-14, can act both as positive and negative
regulators of angiogenesis in tumor vasculature. Moreover,
MMPs can promote EMT by proteolytic activation of TGF-𝛽,
and the same activation can be involved in the suppression
of T-lymphocyte reaction against cancer cell proliferation
(revised in [10, 27]).
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Matrix metalloproteinases family consists of more than
20 zinc-dependent endopeptidase enzymes, sharing a similar
structure, with the ability to degrade almost all components of
the ECM.MMPs facilitate tissue remodeling and normal and
pathological cell migration, functions that allow malignant
cells in cancer to invade andmove through thematrix barrier.
Based on their domain structure and substrate preference,
MMPs are traditionally grouped into (1) collagenases, includ-
ing MMP-1, -8, -13; (2) stromelysins, MMP-3 and MMP-10;
(3) gelatinases, MMP-2 andMMP-9; (4) matrilysins, MMP-7
and MMP-26; (5) membrane-type MMPs (MT-MMPs); and
others (Table 1) [28].
All MMPs are synthesized as zymogens or pro-MMPs
and, with the exception of the membrane bound MT-
MMPs, are secreted and can be activated by a proteolytic
cleavagemechanism [28].The proteolytic activity ofMMPs is
mainly regulated by tissue inhibitors ofMMPs (TIMPs). Four
TIMPs (TIMP-1, TIMP-2, TIMP-3, and TIMP-4) have been
described and they can inhibit all active MMPs, however, not
with the same efficacy [29].
It has recently been postulated that some MMPs have
a protective role in cancer. Mainly, the tumor suppressor
role of these MMPs is related to their ability to degrade
plasminogen, collagen XVIII, and collagen IV to produce
natural angiogenic inhibitors, such as angiostatin, endostatin,
and tumstatin [4]. MMP-8 expression can be used as a good
prognostic marker in breast cancer, while MMP-3, MMP-11,
andMMP-19 have been found to play dual roles in cancer, and
theymay exert protumorigenic or suppressor roles depending
on the tumor context [30].
5. MMPs Activate TGF-𝛽 in
the Extracellular Matrix Compartment
TGF-𝛽 andMMPsmay function in a bidirectional regulatory
loop associated with cancer development, TGF-𝛽 needs to be
proteolytically activated byMMPs in order to exert its cellular
functions, whereas activated TGF-𝛽 in tumors modulates the
balance of ECM remodeling by regulating the expression
of MMPs and their tissue inhibitors TIMPs [10, 31]. TGF-
𝛽 is translated as a homodimeric precursor, a 75 kd protein,
which consists of the signaling peptide, latency-associated
peptide (LAP), and the mature TGF-𝛽. Intracellularly, the
precursor is cleaved by the furin-type convertase producing
the small latent complex (SCL), where the 25 kd dimeric
TGF-𝛽 remains attached to LAP. Next, SCL and the latent
TGF-𝛽 binding protein (LTBP) form the large latent complex
(LCC), which after secretion remains covalently associated
with the ECM. In the ECM, the activation of TGF-𝛽1
involves the proteolytic cleavage of LAP by solubleMMP-9 or
MMP-9 bound to CD44 in the cell-surface, MMP-2, MMP-
13 or MMP-14 [32, 33]. Given that cancer cells frequently
develop resistance to the TGF-𝛽 suppressive tumor effects,
it is suggested that the activation of TGF-𝛽 by MMPs can
have profound tumor-promoting effects by selectively driving
stroma-mediated invasion and metastasis of the tumor [10].
Table 1: Classification of matrix metalloproteinases (adapted from
[28, 37]).
Subclasses of MMPs Name
Interstitial




MMP-14, -15, -16, -17, -24, -25




Others MMP-19, -21, -23a, -27, -28
6. Regulation of MMPs Expression by TGF-𝛽
TGF-𝛽 is able to stimulate several MMPs in cancer cells.
This effect on MMPs can be due to its capacity to activate a
plethora of signal transduction pathways and different tran-
scription factors other than Smads, showing the complexity
in the capacity of TGF-𝛽 to regulate MMP expression in
cancer cells. Smads and several other response elements in
MMP promoters by which TGF-𝛽 may control the MMPs
expression at transcriptional levels have been described.
At least two different regulatory domains have been
described: (1) TGF-𝛽 inhibitory element, TIE, (2) and the
Smad binding element (SBE) [1, 34–36]. SinceMMP-1,MMP-
7, MMP-9, MMP-13, and MM-P14 contain TIE binding
sites in their promoters, it is postulated that the expression
of these MMPs may be modulated by TGF-𝛽 [37, 38]. It
has been demonstrated that TGF-𝛽 negatively regulates the
transcription of MMP-1 and MMP-7 [39–41]. Conversely,
molecular analysis revealed that the consensusTIE in the pro-
moters of MMP-9, MMP-13, and MMP-14 was not required
for their induction by TGF-𝛽 [42–44]. In addition, Smads,
by interacting with the members of the AP1 family, can
alter MMPs expression [45–47]. TGF-𝛽 regulates MMP-13
gene expression partly via the AP1 site and partly through
interactions of Smad3with JunB andRunx-2 [48]. TGF-𝛽 also
directly activates other transcription factors implicated in the
regulation of MMPs expression; it induces cell signaling that
culminates in the transactivation of AP1, PEA3, NF𝜅B, SP1,
andMEF-2 transcription factors to enhanceMMP promoters
transactivity [45, 49–52].
TGF-𝛽 activates a plethoric set of intracellular signaling
pathways that may explain its wide role in cancer, as well as
its profound impact in the regulation of MMPs (Figure 1).
For example, TGF-𝛽 can induce the expression of MMP-2 by
activating TAK1-p38 MAPK in breast epithelial cells [52, 53],
while it enhances SW1990 invasiveness by stimulatingMMP-
2 expression through the activation of Rac1/ROS/NF𝜅B [54].
Meanwhile, MMP-9 has been shown to be upregulated by
TGF-𝛽 through the activation of ERK1,2, Rac1-ROS-NF𝜅B,
and TAK1-NF𝜅B in transformed keratinocytes, breast, and
hepatocellular carcinoma cells [55–59].
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7. The Roles of TGF-𝛽 and MMPs in
Tumor Stroma
Tumors present a highly dynamic integral entity; therefore it
is becoming more apparent that the study of the molecular
processes in tumor biology requires paying attention to all
the components of the tumor. For many decades studies have
been developed in the point of view of transformed cancer
cells, which have been the main targets for oncotherapies.
Transformed cells show the ability to interact with their
microenvironment, and these mutual interactions are what
may drive the tumor progression.
In solid cancers, the tumor stroma, tumor microen-
vironment, or host tissue stroma can be defined as the
nonepithelial compartment surrounding the tumor cells [5,
60].The tumor stroma is a complex structure consisting of the
basement membrane and ECM supportive proteins, includ-
ing extracellular molecules such as cytokines and growth
factor; fibroblasts and cancer associated fibroblast (CAFs);
tumor vasculature to supply nutrients and oxygen (lymphatic
and blood vessels); and immune cells from the lymphoid
(T lymphocytes) and myeloid linages (tumor associated
monocytes/macrophages, neutrophils, dendritic cells, and
myeloid precursor cells) [61–63]. Tumor stroma is a dynamic
structure whose interactions with the epithelial cancer cells
result in reciprocal influence. Interestingly, stroma cells may
generate a tolerant or inductive microenvironment for tumor
progression; for example, the interaction between tumor cells
and stroma cells, such asCAFs andmyofibroblast, triggers the
secretion of growth factors and cytokines for the stimulation
of tumor angiogenesis and may induce profound ECMmod-
ifications, sustaining cancer initiation, progression, growth,
survival, and finally the metastasis process [61, 62, 64].
Deregulation of TGF-𝛽 and MMPs expression and acti-
vation is frequently observed in tumor tissues and has
been shown to contribute to tumor progression [2, 65]. As
mentioned before, TGF-𝛽 acts as tumor suppressor in early
stages of cancer development, while it promotes tumor pro-
gression and metastases in late stages. Interestingly, ablation
of T𝛽RII in stromal fibroblasts promotes carcinoma growth
and invasion, indicating a regulatory loop of TGF-𝛽 signaling
between epithelial cancer cells and the stromal compartment
(revised in [2]). MMPs are mainly involved in the recycling
of ECM as well as in releasing growth factors and cytokines
from ECM. TGF-𝛽 is a potent inductor of the chemotaxis
of immune cells within tumor, stimulating the migration of
lymphocytes, monocytes, and neutrophils, among other cells
[66]. In turn, these cells produce and secrete into the tumor
stroma several MMPs [10, 65], which can release and activate
latent ECM-associated TGF-𝛽 and also regulate immune
cells function, together supporting cancer cells escape from
immune surveillance (Figure 2) [27].
TGF-𝛽 and MMPs form an intricate network, regulated
on many levels, which is why the perturbations in this
network can contribute to the pathogenesis of malignant
tumors. The contribution of TGF-𝛽 and MMPs expression
and secretion in tumor is confined to all cellular compo-
nents; therefore, we will next discuss the interplay between
TGF-𝛽, MMPs, and immune cells with the emphasis on
monocytes/macrophages, neutrophils, and dendritic cells,
which together contribute to tumor development.
8. TGF-𝛽 and MMPs Functionality in Immune
Cells within the Tumor Microenvironment
8.1. Inflammation Can Initiate and Promote Tumor Growth.
In 1986,Dvorak [67, 68] described human tumors as “wounds
that do not heal.” Intriguingly, the changes occurring in the
tumor stroma during cancer progression resemble the pro-
cess associated with chronic inflammation [68]. The primary
role of the inflammatory response is to restrain and eliminate
harmful body aggressors; such is the case of transformed
cancer cells and the subsequent recruitment of antitumor
immune cells to the cancer occurring tissue [68]. Beside the
primary inflammatory response, chronic inflammation may
be beneficial for the tumor development, since the changes
in the tumor microenvironment can convert inflammation
response to a tumor-supporting inflammatory process.
Several cancer types have been proven to be in correlation
with previous chronic inflammatory conditions, manifested
due to infection (e.g.,Helicobacter pillory and gastric cancer),
cryptogenic inflammatory states (e.g., chronic prostatitis and
prostate cancer) or autoimmune diseases (e.g., inflammatory
bowel disease and colon cancer), [69, 70]. However, tumors
that are not potentially induced by inflammation are also
characterized by the presence of the inflammatory compo-
nent in their microenvironment [71].
8.2. Inflammatory Microenvironment in Tumor. The inflam-
matory microenvironment in the tumor includes the pres-
ence of host leukocytes both in the supporting stroma
and among the tumor cells, with macrophages, dendritic
cells, mast cells, neutrophils, and T cells being differentially
distributed [63, 70, 71]. Besides the cellular component, this
microenvironment is rich in inflammatory cytokines, growth
factors, chemokines, and matrix degrading enzymes, which
again induce the recruitment and the specific behavior of the
cellular part.
9. TGF-𝛽 and MMPs in Inflammation
TGF-𝛽 plays an important role in the control of inflamma-
tion. It may negatively regulate immune cell response by acti-
vating regulatory T cells (Tregs) and by inhibiting immune
cells proliferation, while it can induce Th17 differentiation
and enhance the secretion of proinflammatory cytokine IL-
17 [66, 72]. One of the first studies implying TGF-𝛽 as a
regulator of inflammation is coming from the characteristics
found in TGF-𝛽 knockout mice, which died from multifocal
inflammation and autoimmune disorders in internal organs,
suggesting TGF-𝛽 as an immune suppressive factor [66].
Multiple types of immune cells can be regulated by TGF-𝛽
(revised in [72]).The followingmechanisms are proposed: (1)
suppression of the effectorTh cell differentiation; (2) conver-
sion of naive T cells into regulatory T cells; (3) inhibition of
the proliferation of T cells and B cells; (4) inhibition of the
effector cytokine production, such as IL-2, IFN-𝛾, and IL-4;
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Figure 2: TGF-𝛽-MMPs system and tumor stroma-infiltratingmyeloid cells interplay during tumor progression.MMPs produced by resident
tumor stroma cells, such as cancer associated fibroblast (CAFs) or pericytes, may activate latent TGF-𝛽, and both can enhance the recruitment
of immune cells, leukocytes, and myeloid cells to the tumor stroma. TGF-𝛽, in turn, may regulate myeloid cells phenotype, to promote the
protumorigenic M2 phenotype of tumor-associated macrophages (M2-TAMs) and the N2 phenotype of the tumor associated neutrophils
(N2-TANs). At the same time, TGF-𝛽 regulates mast cells degranulation and stimulates the expression of IL-6. In addition, mast cells produce
TGF-𝛽, incrementing the level of the factor in tumor stroma. Meanwhile, TGF-𝛽maintains dendritic cells (DC) in an immature stage, which
in turn, can activate regulatory T cells (Tregs) to enhance immunosuppression. Stimulated Tregs in concert with mast cell produce IL-6 and
induce the differentiation of Th17 cells which in turn may collaborate in the proinflammatory tumor response. Tumor stroma-infiltrating
myeloid cells also produce large amounts of MMPs which can intensify TGF-𝛽 activation, and the TGF-𝛽-MMPs-myeloid cells interplay to
induce a tumor growth permissive stroma supporting tumor progression, thus strengthening the cancer cells invasion and metastasis.
and (5) suppression of macrophages, dendritic cells (DCs),
and natural killer (NK) cells.
Increase in MMPs expression has been seen in almost
every human tissue suffering inflammation (revised in [73]).
Diverse inflammatory processes regulated by MMPs are
dependent on multiple factors, such as MMPs expression,
location, proteolytic activity, and substrate availability.MMPs
may be involved in the degradation and remodeling of
physical barriers and modulation of inflammatory mediators
such as cytokines and chemokines, and by establishing
chemokine gradients in inflamed tissues they can regulate
the movement of immune cells to the affected tissues [10,
73]. Immune myeloid-derived cells, including macrophages,
neutrophils, dendritic cells, and mast cells, produce and
secrete MMPs within tumor stroma, which in turn exert and
control multiple processes controlling tumor angiogenesis,
cancer growth, and metastatic dissemination [10, 65].
10. Tumor Stroma-Infiltrating Myeloid Cells
Myeloid cell subpopulations, such as neutrophils, mono-
cytes/macrophages, and dendritic cells, are key mediators
of inflammatory and innate immune response (revised
in [74]). Although these subpopulations share phagocytic
activity, immunophenotype, origin, and cell turnover, they
display different roles in inflammation, as neutrophils
can amplify inflammation by releasing cytotoxic granules,
whereas macrophages terminate inflammation and restore
tissue integrity after removal of the inflammatory stimuli
[74–76]. Myeloid cells also play important roles in adaptive
immune responses during inflammation, since dendritic
cells can activate antigen specific T cells, while neutrophils
and macrophages suppress T-cell response, thus leading the
concept of myeloid suppressor cells (MDSCs).
Tumors present an environment of unresolved inflamma-
tion initiated by malignant cells. During tumor development,
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myeloid cells accumulate massively within the tumor and
regulate inflammatory and immune responses [74]. Further
on, we will focus on the role of TGF-𝛽 andMMPs inmyeloid-
infiltrating tumor stroma.
10.1. Tumor-Associated Macrophages. Themajor components
of the inflammatory lymphoreticular infiltrates of tumors
are tumor-associated macrophages (TAMs) which have been
implicated in tumor proliferation, progression, and invasion.
TAMs are initially mobilized from the bone marrow and
recruited to the tumor site by specific tumor-derived stimuli
and inflammatory CC chemokines (e.g., CCL2), while their
recruitment and survival are sustained by cytokines present
in the tumor microenvironment (e.g., CSF and VEGF-A)
[70]. High TAM content in human epithelial tumors usually
links to poor prognosis with few exceptions [77]. The critical
function of TAMs has also been documented in the MMTV-
PyMT transgenic mouse model of breast cancer. Crossing
the PyMT breast cancer mice with the macrophage-deficient
CSF1op/op mice suppressed tumor angiogenesis, tumor pro-
gression, and lungmetastasis, whereas primary tumor growth
remained largely unaffected [78].
Macrophages can exert dual functions in the context of
tumors. Namely, TAMs can express M1 or M2 phenotype
depending on the specific stimuli in their microenviron-
ment. M1 macrophages activated by interferon and bacterial
products can elicit tumor and tissue-destructive reactions
by targeting cancer cells and the tumor vasculature and
can therefore be acknowledged as “tumor destructing.” In
contrast, in response to tumor derived or lymphocyte derived
signals [79, 80], TAMs infiltrate the tumor tissue where they
are set in an M2, alternative activation mode, promoting cell
proliferation, angiogenesis, and tissue remodeling, thus being
“tumor promoting.” M1 and M2 cells are extremes in a con-
tinuum of functional states [70, 81, 82] susceptible to change
dependent on the factors present in their microenvironment.
TGF-𝛽 promotes recruitment of monocytes and it may
promote monocyte to macrophage differentiation [2]. In the
innate immune response, TGF-𝛽 promotes TAMpolarization
to an M2-versus-M1 phenotype, which further promotes
TGF-𝛽 production and deepens immunosuppression [83,
84].
In response to cytokines such as TGF-𝛽, IL-10, and
macrophage colony-stimulating factor (M-CSF), TAMs can
promote tumor proliferation and progression and stroma
deposition, while also contributing to the remodeling and
inhibition of adaptive immunity [85–87]. Several studies in
human cancer have shown that TAMs accumulation is asso-
ciated with increased angiogenesis and with the production
of angiogenic factors such as VEGF and platelet-derived
endothelial cell growth factor. It is believed that macrophages
do not participate in angiogenesis unless activated and
hypoxia is known to trigger a proangiogenic program in
TAMs, as these cells accumulate in hypoxic regions of tumors.
Furthermore, TAMs inhibit antitumor immunity by secreting
TGF-𝛽, leading to an increase in angiogenesis and the
expression of growth factors involved in supporting tumor
growth [63]. Many of the observed functional responses of
macrophages to TGF-𝛽may be attributed to the regulation of
gene expression of inflammatorymediators. In macrophages,
TGF-𝛽 has been shown to suppress the expression ofMIP-1𝛼,
MIP-2, CXCL1, IL-1𝛽, IL-8, GM-CSF, and IL-10 [2, 88].
Tumor invasion can be induced by macrophages through
the production of enzymes and inhibitors that regulate the
digestion of the ECM, as well as through the production of
several MMPs including MMP-1, MMP-2, MMP-7, MMP-9,
MMP-12 and MMP-14 [10]. For example, MMP-9 has com-
plex effects beyondmatrix degradation, including promotion
of the angiogenesis switch and release of growth factors [69].
In amousemodel for cervical cancer, inhibition ofMMP-9 in
macrophages blocked the release of VEGF and thereby inhib-
ited angiogenesis and tumor growth [89]. Although almost
all of these MMPs have been implicated in the enhancement
of tumor cell malignance by increasing angiogenesis and
tumor invasiveness, MMP-12 has been implicated in the
generation of angiostatin, and the mice deficient in MMP-12
showed an enhancement in the development of Lewis lung
carcinoma metastases, suggesting TAM-produced MMP-12
as suppressive for the growth and malignance of lung cancer
cells [90]. In addition, TGF-𝛽1 inhibited cytokine-mediated
induction ofMMP-12mRNA, protein, and enzymatic activity
induced by cytokines [91]. TAMs also produce factors, such
as PDGF, IL-6, uPA, and tissue-type plasminogen activator
(t-PA) that may cause matrix degradation.
These data strongly suggest that macrophages play a role
in both angiogenesis initiation in avascular areas and in the
remodeling of the vasculature once formed to give coherent
vascular flow [86]. TGF-𝛽1 also increases the expression of
fetal liver kinase-1 (Flk-1), a major VEGF receptor, and TGF-
𝛽1 and VEGF stimulateMMP-9 expression, respectively, thus
increasing the invasiveness of cancer cells [92].
Finally, the specific deletion of TBRII in myeloid cells
produces TAMs unresponsive to TGF-𝛽, with downregula-
tion in basal IL-6 secretion. Most importantly, TGF-𝛽 does
not induce any VEGF response in these cells, and decreased
MMP-9 and increased MMP-2 and iNOS expression were
noted, along with the increase in antigen-antitumorigenic
properties of TAMs [93].
10.2. Tumor-Associated Neutrophils. Neutrophils are the pre-
dominant circulating leukocyte population in humans,
accounting for 50–70% of circulating leukocytes. They have
been seen in vivo in close association with tumor cells and
within tumor vasculature [94, 95]. Recently, neutrophils have
emerged as new tumor-infiltrating myeloid cells, playing
an important role in tumor growth and progression [96].
Similarly to macrophages, neutrophils may also have both
protumoral and antitumoral roles [97].
Tumor-associated neutrophils (TANs) can stimulate
tumor growth by stimulating angiogenesis through the pro-
duction of proangiogenic factors, including VEGF, IL-8, and
MMPs [98, 99]. Recent findings suggest the N1-N2 polariza-
tion model of TANs, similar to the M1-M2 model for TAMs
[100]. This group suggested specific classification of TANs
according to which these cells can have antitumorigenic (N1)
phenotype versus protumorigenic (N2) phenotype.
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Depletion of “protumorigenic” N2 neutrophils, therefore,
inhibits tumor growth and reduces the level of immunosup-
pression in the tumor microenvironment, allowing increased
activity of cytotoxic T lymphocytes [95, 101]. The antitumor
activities of N1 type of TANs include expression of more
immunoactivating cytokines and chemokines, lower levels
of arginase, and more capability of killing tumor cells in
vitro. Blockade of TGF-𝛽 favored the accumulation of N1
TANs, suggesting that TGF-𝛽 is a major proximal cytokine
within tumors that defines the TAN phenotype and shifts
differentiation toward the N2 protumorigenic phenotype
[100]. Interestingly, preliminary data suggested that at least
part of the neutrophil-attracting chemokines is derived from
TAMs, suggesting a “ménage á trois” involving T cells,
macrophages, and neutrophils [102]. Interestingly, TGF-𝛽
may inhibit neutrophils adhesion and endothelial cell trans-
migration in vitro and in different inflammatory disease
state as well [95]. Another point of TGF-𝛽 regulation of the
inhibition of suppressive roles of neutrophils is the capacity
of TGF-𝛽 to decrease the ability of neutrophils to eliminate
Fas ligand expressing cancer cells, one of the main functions
of neutrophils in tumor microenvironment, thereby creating
a stroma permissive for tumor progression [103].
Neutrophils have a role in the initiation of carcinogenesis,
mainly by regulating the ECM turnover which can have pro-
found effects on the tumor microenvironment. A key media-
tor secreted from neutrophils and involved in carcinogenesis
isMMP-9.MMP-9 has been demonstrated to play key roles in
tumorigenesis participating in the progression of cancer cells
to more invasive and metastatic stages. Interestingly, MMP-9
secreted by neutrophils or by other cells in the tumor stroma
may prevent apoptosis of cancer cells [95, 104].
Neutrophils’ granules contain large amounts of MMP-
9. Moreover, serine proteases released by these cells acti-
vate MT1-MMP, a membrane bound MMP that activates
pro-MMP-2, leading to an increase in active MMP-2. On
the other hand, MMPs can recruit neutrophils to sites of
inflammation, which requires the extravascular migration of
neutrophils through the extracellular matrix. Furthermore,
TGF-𝛽1 stimulates degranulation of adherent human neu-
trophils [105]. Enzymes released by the neutrophils within
the tumor milieu can activate latent proteases and diminish
cell-cell interactions, thereby permitting the dissociation of
tumor cells from the main tumor mass. The embedded
growth factors and chemoattractants released during ECM
remodeling, such as basic fibroblast growth factor, could
serve both as chemoattractants and growth factors for these
tumor cells [106].
Conversely to the protumorigenic properties of neu-
trophils, several studies have reported the antitumorigenic
roles for these cells. For example, during TGF-𝛽 inhibition,
neutrophils can inhibit tumor growth by assuming a tumor-
cytotoxic N1 phenotype, and depletion of these N1 TANmay
either enhance tumor growth and/or decrease the antitumor
effects of immunologic treatments [95, 100].
Neutrophils may also exert their antitumor activities by
expressing and secreting MMP-8, which is mainly produced
by neutrophils and has been postulated as a tumor suppressor
[107]. The loss of MMP-8 increased skin susceptibility to
chemical carcinogens in mice. Intriguingly, the absence of
MMP-8 prevents the influx of neutrophils to the site of
carcinogenesis induction [108]. Whether TGF-𝛽 regulates
MMP-8 expression in neutrophils has not been well eluci-
dated yet, although TGF-𝛽may decrease MMP-8 expression
in human odontoblast [109], and it may be of interest to
explore if N2 transition induced by TGF-𝛽 requires down-
regulation of MMP-8.
It has recently been described that MMP-8 expression in
breast cancer cells provokes a reduction in the microRNA-
21 (miR-21), which may predict a recurrence and unfavorable
survival in nonsmall cell lung cancer [110].ThemiR-21 in turn
is induced by TGF-𝛽 during the EMT [111]. The reduction of
miR-21 expression by MMP-8 in turn leads to the inhibition
of tumor growth and lung metastasis subsequently with a
reduction of TGF-𝛽 signaling, thus indicating a new way for
MMP-8 contribution to decrease tumor progression [112].
10.3. Tumor-Associated Dendritic Cells. Dendritic cells (DC)
are critical regulators of host immune response that serve
as a bridge between innate and adaptive immunity [113].
Dendritic cells play an essential role in the activation of
specific immunity since they are the most effective antigen-
presenting cells. However, tumor associated dendritic cells
(TADCs), which infiltrate neoplastic tissues in response to
tumor-derived chemokines, are functionally defective as they
have an immature phenotype because of the immunosup-
pressive cytokines in the tumor microenvironment, such as
TGF-𝛽 and IL-10 [81, 114]. Immature myeloid DCs promote
the expansion of Treg cells associated with TGF-𝛽-dependent
tumor progression [115]. Therefore, TADCs promote T-cell
anergy to tumor antigens and Treg activity [70].
Improvements in dendritic cell function may be possible
through the inhibition of TGF-𝛽 (revised in [116]). TGF-
𝛽 regulates the antigen presentation function of differenti-
ated dendritic cells, and exogenous TGF-𝛽 administration
to lipopolysaccharide-stimulated dendritic cells inhibits the
expression of MHC class II and costimulatory molecules.
Also, TGF-𝛽 inhibits the IL-1 and TNF-𝛼-induced IL-12
production by DCs. This may result in the inhibition of T-
cell activation anddifferentiation of their antitumor activities,
indicating that the blocking of TGF-𝛽 signaling in DCs
is a rational therapy to enhance its suppressive role in
cancer development [117]. Conversely, it is possible that these
tumor-infiltrating dendritic cells could play a role in the
immune response to tumors by processing antigenic proteins
released by adjacent tumor cells and presenting immuno-
genic peptides to competent T cells either inside the tumor
or after migration into lymphoid organs [118]. Once more,
the balance between antitumorigenic and protumorigenic
character of cells is dependent on the switch made by the
cytokines in the microenvironment.
Dendritic cells produceMMP-1, MMP-2, MMP-3, MMP-
9,MMP-12,MMP-14 andMMP-19 [10, 119, 120]. Overproduc-
tion of these MMPs by DCs during infection is associated
with a decrease in endothelial PECAM-1 and VE-cadherin
in vascular endothelium in vitro and in vivo, which may
contribute to the marked increase in vascular permeability.
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Thus, opening of endothelial barriers by MMP activity may
be a mechanism that allows passage of plasma proteins and
inflammatory cells into otherwise privileged compartments.
However, further research is necessary to investigate whether
the behavior of TADCs is similar to that during infection.
10.4. Mast Cells. Mast cells are bone marrow-derived tissue-
homing leukocytes; these cells seem to be significant for
a variety of biological functions, such as tissue repair and
regeneration, angiogenesis, inflammation, and cancer [121].
It has been suggested that mast cells can either promote
tumor progression or, supported by clinical data, display
some tumor suppressive effects [122]. The tumor secretion of
stem cell factor functions as a chemoattracting signal formast
cells; then mast cells produce angiogenic factors and MMPs
(MMP-2 and MMP-9) to promote tumor vascularization.
In the same way, TGF-𝛽 is suggested as one of the most
potent attractants for mast cells, since TGF-𝛽1 has been
shown to cause directed migration of cultured mouse mast
cells [123], and might indicate the possibility that the incre-
ment of TGF-𝛽 production in the tumor stroma attracted
mast cells to the site of tumor. Mast cells produce TGF-𝛽
which can also act as a pro-angiogenic factor and strongly
regulates Tregs within tumors; in turn Tregs inhibit mast
cell progenitors and suppress degranulation of mature mast
cells in a TGF-𝛽-related fashion. Mast cells in turn inhibit
expression of IL-10 by Tregs and promote differentiation of
proinflammatoryTregs [124, 125], thus suggesting an immune
cell loop during the cancer promotion. Intriguingly, TGF-
𝛽 enhances IL-6 expression and secretion in mast cells,
which in turn enhances Th17 differentiation [126]. The IL-
17 production by mature Th17 may promote tumor growth
and provide resistance to antiangiogenic therapy [127–130],
which may provide an indirect way of TGF-𝛽 and mast cells
protumorigenic activities.
Mast cells are essential for late stages of tumor expansion,
as is demonstrated by the ablation of mast cells which
provoked an increment of tumor cells apoptosis and reduced
tumor vascularization. Mast cells also were important for the
induction of angiogenesis by expressingMMP-9, sinceMMP-
9 deficiency highly impaired the incidence of invasive tumors
in skin carcinogenesis [131, 132]. In rats, the injection of mast
cells leads to the acceleration of tumor development. Mast
cell enhancement of tumor proliferation was demonstrated
by the addition of mast cells to the initial tumor inoculum
and by pharmacological inhibition of mast cell degranulation
[133]. During the degranulation, mast cells released MMP-2
and MMP-9, as well as other proteases, which can activate
latent MMP-3 and MMP-9 [134, 135]. The presence of mast
cells can provide the changes necessary for the induction of a
permissive tumor stroma, and TGF-𝛽 and MMPs secreted,
together with the other myeloid-infiltrating tumor stroma,
may collaborate to promote tumor development and cancer
cell invasiveness.
10.5. Concluding Remarks. It is believed that TGF-𝛽 and
MMPs produced by the epithelial cancer and local stroma
cells contribute to the progression and metastatic potential
of tumor, acting on the delicate balance between the matrix
and the cellular components in the tumor body, on which the
success of cancer development depends.
TGF-𝛽 modifies the expression, secretion, and activa-
tion of MMPs, which in a mutual response activate latent
TGF-𝛽 from ECM. In addition, active MMPs increase the
bioavailability of cytokines and growth factors that promote
tumor cell proliferation, survival, and invasion, as well as
tumor angiogenesis to support tumor growth and metastasis.
TGF-𝛽 and MMPs contribute to the recruitment of MMP-
producing immune cells into tumor, such as neutrophils,
macrophages, and mast cells, and also suppress their anti-
tumor activity. In addition, these cells in response to TGF-
𝛽 can produce angiogenic factors (such as VEGF) which
contribute to tumor angiogenesis. Finally, locally active TGF-
𝛽 strongly contributes to the immunosuppressive effects of
the tumor cells, by suppressing the activity of cytotoxic T
cells, dendritic cells, and natural killer cells allowing tumor
to escape/evade the immune cell response. Finally both TGF-
𝛽 and MMPs production stimulates carcinoma cell growth,
motility, and invasion.
All the cells present in tumor stroma, including inflam-
matory cells, as well as tumor cells are able to produce TGF-
𝛽, while types of MMPs secreted are cell type specific. The
main loop in the tumor inflammatory environment would
be inflammatory cells (M2-TAMs and N2-TANs especially),
production of TGF-𝛽 and MMPs, reciprocal upregulation of
TGF-𝛽 and MMPs, and consequent recruitment of inflam-
matory cells closing the loop (Figure 2). At the same time,
all three members of the loop have been shown to induce
cancer growth and invasion by inducing angiogenesis, by
degrading ECM, or by cytokine and chemokine production.
The fine tuning of the cells’ “antitumorigenic” against “pro-
tumorigenic” phenotype is regulated in big part by TGF-𝛽,
subsequently involving a vast number of different cytokines,
chemokines, and enzymes, all together defining the final
direction of the tumor. Finally, the system in whole as well
as its single participants is balancing between the “good” and
“bad” influence, acting against or promoting tumor growth
and invasion.The details of fine regulation of tumor behavior
are complex and yet to be elucidated.
The understanding of the mechanisms by which TGF-𝛽,
MMPs, and tumor stroma-infiltrating myeloid cells act may
open new avenues which will develop more precise therapies
for cancer treatment. Several oncotherapies and clinical
trials are ongoing for the components of TGF-𝛽 signaling
[1], and more specific inhibitors have been developed to
surgically inhibit MMPs as well [136]. Because some MMPs,
such MMP-8 and MMP-12, can be beneficial as antitumor
targets, a broad MMP targeting is not recommended, as
already demonstrated by the unsuccessful use of broadMMP
inhibitors in experimental cancer assays [107]. Due to the fact
thatmany studies have demonstrated the correlation between
the density of TAMs and poor prognosis, macrophages have
also been considered as a target for clinical therapy [84].
The possibility to deplete the macrophages from tumor, by
using a combination of zoledronic acid with sorafenib [137]
or by inhibiting macrophages infiltration, by drugs, such as
thalidomide, linomide, and pentoxifylline [138], may reduce
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the tumor growth; nonetheless, these analyses need to be
translated to human cancer treatment. A novel study has been
recently reported, exploiting membrane mannose receptors
mainly expressed in M2 TAMs as targets for PEG-sheddable
mannose-modified nanoparticles and producing a platform
to carry drugs ormodulatory anti-tumor agents toM2-TAMs
[139].
The regulation of both TGF-𝛽 and protumorigenicMMPs
(e.g., MMP-9) may directly regulate cancer cells growth,
angiogenesis, and invasiveness. TGF-𝛽 blocking may have
profound impact on the balance of M1-M2 TAMs and N1-N2
neutrophils and allow dendritic cells maturation. Blocking
may also regulate the excessive recruitment of the compo-
nents of tumor stroma-infiltrating myeloid cells to finally
drive/guide the immune myeloid cells against tumors. A
combinatory therapy against TGF-𝛽, protumorigenicMMPs,
andmyeloid immune cells may create an antitumormicroen-
vironment more sensitive to traditional chemotherapies of
cancer.
Elucidating the complex interplay and roles of TGF-𝛽
andMMPs in the tumor, including tumormicroenvironment,
cancer cells, stroma-infiltrating myeloid cells, and ECM
interactions, is critical for understanding their participation
in the initiation, progression, metastasis, and eventually
uncovering potential combinatory therapeutic targets for
future treatment of human cancer.
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